Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial

被引:324
|
作者
Eich, Hans Theodor
Diehl, Volker
Goergen, Helen
Pabst, Thomas
Markova, Jana
Debus, Juergen
Ho, Anthony
Doerken, Bernd
Rank, Andreas
Grosu, Anca-Ligia
Wiegel, Thomas
Karstens, Johann Hinrich
Greil, Richard
Willich, Normann
Schmidberger, Heinz
Doehner, Hartmut
Borchmann, Peter
Mueller-Hermelink, Hans-Konrad
Mueller, Rolf-Peter
Engert, Andreas [1 ]
机构
[1] Univ Cologne, Dept Internal Med 1, D-50924 Cologne, Germany
关键词
POSITRON-EMISSION-TOMOGRAPHY; INTERNATIONAL PROGNOSTIC SCORE; NODE RADIOTHERAPY; STAGE-I; DISEASE; CYCLES; PROGRESSION; RADIATION; SUPERIOR; THERAPY;
D O I
10.1200/JCO.2010.29.8018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Combined-modality treatment consisting of four to six cycles of chemotherapy followed by involved-field radiotherapy (IFRT) is the standard of care for patients with early unfavorable Hodgkin's lymphoma (HL). It is unclear whether treatment results can be improved with more intensive chemotherapy and which radiation dose needs to be applied. Patients and Methods Patients age 16 to 75 years with newly diagnosed early unfavorable HL were randomly assigned in a 2 x 2 factorial design to one of the following treatment arms: four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy of IFRT; four cycles of ABVD + 20 Gy of IFRT; four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP(baseline)) + 30 Gy of IFRT; or four cycles of BEACOPP(baseline) + 20 Gy of IFRT. Results With a total of 1,395 patients included, the freedom from treatment failure (FFTF) at 5 years was 85.0%, overall survival was 94.5%, and progression-free survival was 86.0%. BEACOPP(baseline) was more effective than ABVD when followed by 20 Gy of IFRT (5-year FFTF difference, 5.7%; 95% CI, 0.1% to 11.3%). However, there was no difference between BEACOPP(baseline) and ABVD when followed by 30 Gy of IFRT (5-year FFTF difference, 1.6%; 95% CI, -3.6% to 6.9%). Similar results were observed for the radiotherapy question; after four cycles of BEACOPP(baseline), 20 Gy was not inferior to 30 Gy (5-year FFTF difference, -0.8%; 95% CI, -5.8% to 4.2%), whereas inferiority of 20 Gy cannot be excluded after four cycles of ABVD (5-year FFTF difference, -4.7%; 95% CI, -10.3% to 0.8%). Treatment-related toxicity occurred more often in the arms with more intensive therapy. Conclusion Moderate dose escalation using BEACOPP(baseline) did not significantly improve outcome in early unfavorable HL. Four cycles of ABVD should be followed by 30 Gy of IFRT.
引用
收藏
页码:4199 / 4206
页数:8
相关论文
共 50 条
  • [41] Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin's disease: Results of the German Hodgkin's Lymphoma Study Group (GHSG) trial HD7.
    Sieber, M
    Franklin, J
    Tesch, H
    Rueffer, U
    Brillant, C
    Reineke, T
    Herrmann, R
    Boissevain, F
    Franke, A
    Pfreundschuh, M
    Hossfeld, DK
    Wingbermuehle, K
    Josting, A
    Wolf, J
    Paulus, U
    Mueller, RP
    Duehmke, E
    Engert, A
    Diehl, V
    BLOOD, 2002, 100 (11) : 93A - 93A
  • [42] Two cycles of ABVD followed by involved field radiotherapy with 20 Gray (Gy) is the new standard of care in the treatment of patients with early-stage Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group (GHSG) HD10 study
    Engert, A.
    Diehl, V
    Pluetschow, A.
    Eich, H.
    Herrmann, R.
    Doerken, B.
    Kanz, L.
    Greil, R.
    Markova, J.
    Fuchs, M.
    Borchmann, P.
    Mueller-Hermeling, H. K.
    Mueller, R. P.
    ONKOLOGIE, 2010, 33 : 124 - 124
  • [43] TWO CYCLES OF ABVD FOLLOWED BY INVOLVED FIELD RADIOTHERAPY WITH 20 GRAY (GY) IS THE NEW STANDARD OF CARE IN THE TREATMENT OF PATIENTS WITH EARLY-STAGE HODGKIN LYMPHOMA: FINAL ANALYSIS OF THE RANDOMIZED GERMAN HODGKIN STUDY GROUP (GHSG) HD10 STUDY
    Engert, A.
    Pluetschow, A.
    Eich, H.
    Herrmann, R.
    Doerken, B.
    Kanz, L.
    Greil, R.
    Markova, J.
    Fuchs, M.
    Borchmann, P.
    Mueller-Hermelink, H.
    Mueller, R.
    Diehl, V.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 473 - 473
  • [44] High dose chemotherapy and stem cell rescue for aggressive non-Hodgkin's lymphoma: Pattern of failure and implications for involved-field radiotherapy
    Mundt, AJ
    Williams, SF
    Hallahan, D
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 39 (03): : 617 - 625
  • [45] Two Cycles of ABVD Followed by Involved Field Radiotherapy with 20 Gray (Gy) Is the New Standard of Care in the Treatment of Patients with Early-Stage Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group (GHSG) HD10.
    Engert, Andreas
    Diehl, Volker
    Pluetschow, Annette
    Eich, Hans T.
    Herrmann, Richard
    Doerken, Bernd
    Kanz, Lothar
    Greil, Richard
    Markova, Jana
    Fuchs, Michael
    Borchmann, Peter
    Mueller-Hermelink, Hans Konrad
    Mueller, Rolf Peter
    BLOOD, 2009, 114 (22) : 299 - 299
  • [46] Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial
    Behringer, K.
    Thielen, I.
    Mueller, H.
    Goergen, H.
    Eibl, A. D.
    Rosenbrock, J.
    Halbsguth, T.
    Eichenauer, D. A.
    Fuchs, M.
    Reiners, K. S.
    Renno, J. H.
    van der Ven, K.
    Kuehr, M.
    von Wolff, M.
    Diehl, V.
    Engert, A.
    Borchmann, P.
    ANNALS OF ONCOLOGY, 2012, 23 (07) : 1818 - 1825
  • [47] BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation:: German Hodgkin Lymphoma Study Group interim results.
    Diehl, V
    Wolf, J
    Franklin, J
    Engert, A
    Hasenclever, D
    Müller-Hermelink, HK
    Hermann, R
    Tesch, H
    Paulus, U
    Loeffler, M
    ANNALS OF ONCOLOGY, 2000, 11 : 99 - 100
  • [48] Response to low-dose involved-field radiotherapy (LD-IF-RT) in patients with non-Hodgkin's lymphoma (NHL)
    Luthy, S. K.
    Ng, A. K.
    Freedman, A. S.
    Silver, B.
    Mauch, P. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S532 - S532
  • [49] Mortality during treatment of patients with advanced Hodgkin's lymphoma undergoing dose escalated BEACOPP chemotherapy: An analysis of the German Hodgkin study group (GHSG).
    Fuchs, M
    Franklin, J
    Klimm, B
    Josting, A
    Pfistner, B
    Engert, A
    Diehl, V
    BLOOD, 2005, 106 (11) : 749A - 749A
  • [50] Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial
    Advani, R. H.
    Hoppe, R. T.
    Baer, D.
    Mason, J.
    Warnke, R.
    Allen, J.
    Daadi, S.
    Rosenberg, S. A.
    Horning, S. J.
    ANNALS OF ONCOLOGY, 2013, 24 (04) : 1044 - 1048